Watch MYGN. Know when insiders buy.
One email the day a filing lands. Free.
MYGN
MYRIAD GENETICS INC
5.57
+0.03 +0.54%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $532.8MP/E —DIV YIELD —FCF YIELD —REV TTM $806.6M −3.2%NET INCOME −$112.6MNET DEBT $5.5M52W 2.86 – 8.18SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $190.7M | −10.5% | 66.6% | −$38.9M | −$43.2M | — | -0.46 | −$8.3M | — | — | Jul 31 |
| Q1 2026 · Mar 31 | $200.4M | +2.3% | 68.7% | −$30.7M | −$34.1M | — | -0.36 | −$15.7M | — | — | Jul 31 |
| Q4 2025 · Dec 31derived | $209.8M | −0.4% | 70.0% | −$5.7M | −$7.9M | — | -0.07 | $10.6M | — | — | Feb 24 |
| Q3 2025 · Sep 30 | $205.7M | −3.6% | 69.9% | −$23.3M | −$27.4M | — | -0.29 | $21.1M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | $213.1M | +0.8% | 71.2% | −$329.2M | −$330.5M | — | -3.57 | −$13.6M | — | — | Jul 31 |
| Q1 2025 · Mar 31 | $195.9M | −3.1% | 68.5% | −$29M | −$100K | — | 0.00 | −$16.3M | — | — | Jul 31 |
| Q4 2024 · Dec 31derived | $210.6M | +7.1% | 71.7% | −$39M | −$42.5M | — | -0.47 | $6.6M | — | — | Feb 24 |
| Q3 2024 · Sep 30 | $213.3M | +11.2% | 70.2% | −$20M | −$22.1M | — | -0.24 | $700K | — | — | Nov 4 |
| Q2 2024 · Jun 30 | $211.5M | — | 69.6% | −$36.5M | −$36.7M | — | -0.41 | $2.6M | — | — | Nov 4 |
| Q1 2024 · Mar 31 | $202.2M | — | 68.1% | −$27.9M | −$26M | — | -0.29 | −$18.6M | — | — | Nov 4 |
| Q4 2023 · Dec 31derived | $196.6M | — | 68.7% | −$31.4M | −$31.2M | — | -0.34 | −$54.7M | — | — | Feb 24 |
| Q3 2023 · Sep 30 | $191.9M | — | 70.0% | −$60.1M | −$61.3M | — | -0.75 | −$22.1M | — | — | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $824.5M | 69.9% | −$387.2M | −$365.9M | -44.4% | -3.95 | $1.8M | — | — | — | — |
| FY2024 · to Dec 31 | $837.6M | 69.9% | −$123.5M | −$127.3M | -15.2% | -1.41 | −$8.7M | — | — | — | — |
| FY2023 · to Dec 31 | $753.2M | 68.6% | −$257.4M | −$263.3M | -35.0% | -3.18 | −$110.9M | — | — | — | — |
| FY2022 · to Dec 31 | $678.4M | 70.2% | −$140.6M | −$112M | -16.5% | -1.39 | −$106.3M | $45.3M | −$151.6M | — | — |
| FY2021 · to Dec 31 | $690.6M | — | −$190.5M | −$27.2M | -3.9% | -0.35 | $18.6M | $18M | $600K | $0 | — |
| FY2020 · to Dec 31 | $557.1M | — | −$289.7M | −$223.6M | -40.1% | -2.99 | — | — | — | — | — |
Every number comes from MYRIAD GENETICS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.